Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2015-11-09 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos builds on strong profile of filgotinib in 7 presentations at ACR 2015
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV dated November 8, 2015, detailing the presentation of results for their drug filgotinib at the American College of Rheumatology (ACR) 2015 Annual Meeting. It summarizes oral and poster presentations, including study results (DARWIN 1 & 2) and pharmacokinetic data. This content is typical of an announcement summarizing scientific findings presented at a medical conference, which often precedes or accompanies a formal Investor Presentation (IP) or is released as a general update. Since it is a detailed summary of research findings presented at a specific event (ACR 2015) and includes an 'About Galapagos' section and contact information, it functions as a comprehensive update for investors regarding scientific progress. It is not a formal regulatory filing (like 10-K or IR), nor is it a transcript (CT) or a simple earnings release (ER). It most closely aligns with an Investor Presentation (IP) content, even if formatted as a press release, as it details clinical data and pipeline progress for investors. Given the options, 'IP' (Investor Presentation) is the best fit for detailed scientific/pipeline updates aimed at investors.
2015-11-09 English
Dr. Christine Mummery treedt toe tot Raad van Bestuur van Galapagos
Board/Management Information Classification · 99% confidence The document is a press release announcing the appointment of Dr. Christine Mummery to the company's Board of Directors. This type of announcement, detailing changes in senior management or the board, directly corresponds to the definition of 'Board/Management Information'. The filing code for this category is MANG.
2015-11-04 Dutch
Dr. Christine Mummery treedt toe tot Raad van Bestuur van Galapagos
Board/Management Information Classification · 99% confidence The document is an announcement dated November 4, 2015, stating that Dr. Christine Mummery is joining the Board of Directors of Galapagos NV as an independent non-executive director. This directly relates to changes in the company's board structure and senior personnel. This aligns perfectly with the definition for Board/Management Information (MANG). It is not an Annual Report (10-K), an Earnings Release (ER), or a general regulatory filing (RNS), as it concerns a specific management change.
2015-11-04 Dutch
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of October 2015. It references an attached press release dated October 9, 2015, but the document itself is a regulatory filing to furnish information under the Securities Exchange Act. The content is brief (2341 characters) and primarily serves as a notification of the press release submission rather than containing detailed financial data or report content. According to the rules, such filings that provide regulatory updates or miscellaneous information that do not fit other categories are classified as Regulatory Filings (RNS).
2015-10-20 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Galapagos NV, pursuant to the SEC rules under the Securities Exchange Act of 1934. Form 6-K is a regulatory filing used by foreign companies to report material information to the SEC between annual reports (20-F or 40-F). The document includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data itself. The document length is short (1514 characters), and it primarily serves as a regulatory announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and does not qualify as an Annual Report, Interim Report, or other specific report types.
2015-10-20 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of October 2015. It references an attached press release dated October 8, 2015, but does not contain substantive financial data or detailed report content itself. The document is relatively short (2341 characters) and primarily serves as a cover report to furnish the press release. According to the rules, such filings that provide a report or document but do not contain the report itself are classified as Regulatory Filings (RNS).
2015-10-20 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.